Pharmacodynamic and clinical endpoints for functional colonic disorders: Statistical considerations

Digestive Diseases and Sciences

Volumn 58, Issue 2, 2013, Pages 509-518

  Zinsmeister, Alan R ^b   Burton, Duane ^a   Camilleri, Michael ^a  

^a Clinical Enteric Neuroscience Translational and Epidemiological Research Mayo Clinic   (United States)

^b Mayo Clinic   (United States)

Author keywords

Constipation; Crossover; Diarrhea; Parallel; Transit

Indexed keywords

CHENODEOXYCHOLIC ACID; COLESEVELAM; DEXLOXIGLUMIDE; ELOBIXIBAT; LINACLOTIDE; PLACEBO; RENZAPRIDE; BENZAMIDE DERIVATIVE; FUSED HETEROCYCLIC RINGS; GASTROINTESTINAL AGENT; PEPTIDE; SEROTONIN ANTAGONIST; VALERIC ACID DERIVATIVE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL (TOPIC); COMPARATIVE STUDY; CONSTIPATION; CORRELATION COEFFICIENT; DIARRHEA; DIGESTIVE SYSTEM FUNCTION DISORDER; EFFECT SIZE; FECES; FEMALE; HUMAN; INTESTINE FUNCTION; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REPRODUCIBILITY; SAMPLE SIZE; COLON DISEASE; CONTROLLED CLINICAL TRIAL (TOPIC); CROSSOVER PROCEDURE; DRUG EFFECT; GASTROINTESTINAL MOTILITY; META ANALYSIS; METHODOLOGY; MIDDLE AGED; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PHYSIOLOGY; SCINTISCANNING;

ADULT; BENZAMIDES; BICYCLO COMPOUNDS, HETEROCYCLIC; CHENODEOXYCHOLIC ACID; CLINICAL TRIALS, PHASE II AS TOPIC; COLONIC DISEASES; CONSTIPATION; CONTROLLED CLINICAL TRIALS AS TOPIC; CROSS-OVER STUDIES; DIARRHEA; FEMALE; GASTROINTESTINAL AGENTS; GASTROINTESTINAL MOTILITY; HUMANS; MALE; MIDDLE AGED; PENTANOIC ACIDS; PEPTIDES; SEROTONIN ANTAGONISTS;

MLCS; MLOWN;

EID: 84876332818     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-012-2369-z     Document Type: Article

References (17)

1. DiMasi JA, Feldman L, Seckler A, Wilson A. Trends in risks associated with new drug development: success rates for investigational drugs. Clin Pharmacol Ther. 2010;87:272-277.
2. Adams CP, Brantner VV. Spending on new drug development1. Health Econ. 2010;19:130-134.
3. Adams CP, Brantner VV. Estimating the cost of new drug development: is it really 802 million dollars? Health Aff. (Millwood). 2006;25:420-428.
4. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69:89-95.
5. Camilleri M. Scintigraphic biomarkers for colonic dysmotility. Clin Pharmacol Ther. 2010;87:748-753.
6. Camilleri M, McKinzie S, Fox J, et al. Effect of renzapride on transit in constipation-predominant irritable bowel syndrome. Clin Gastroenterol Hepatol. 2004;2:895-904.
7. Cremonini F, Camilleri M, McKinzie S, et al. The CCK-1 antagonist, dexloxiglumide, in female patients with irritable bowel syndrome: a pharmacodynamic and pharmacogenomic study. Am J Gastroenterol. 2005;100:652-663.
8. Andresen V, Camilleri M, Busciglio I, et al. Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome. Gastroenterology. 2007;133:761-768.
9. Rao AS, Wong BS, Camilleri M, et al. Chenodeoxycholate in females with irritable bowel syndrome-constipation: a pharmacodynamic and pharmacogenetic analysis. Gastroenterology. 2010;139:1549-1558.
10. Wong BS, Camilleri M, McKinzie S, Burton D, Graffner H, Zinsmeister AR. Effects of A3309, an ileal bile acid transporter inhibitor, on colonic transit and symptoms in females with functional constipation. Am J Gastroenterol. 2011;106:2154-2164.
11. Kim HJ, Camilleri M, McKinzie S, et al. A randomized, controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhea-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2003;17:895-904.
12. Sweetser S, Camilleri M. Linker Nord SJ, et al. Do corticotropin releasing factor-1 receptors influence colonic transit and bowel function in females with irritable bowel syndrome? Am J Physiol. 2009;296:G1299-G1306.
13. Odunsi-Shiyanbade ST, Camilleri M, McKinzie S, et al. Effects of chenodeoxycholate and a bile acid sequestrant, colesevelam, on intestinal transit and bowel function. Clin Gastroenterol Hepatol. 2010;8:159-165.
14. Camilleri M, Vazquez-Roque M, Iturrino J, et al. Effect of a glucagon-like peptide 1 analog, ROSE-010, on gastrointestinal motor functions in females with constipation-predominant irritable bowel syndrome. Am J Physiol. 2012;303:G120-G128.
15. Deiteren A, Camilleri M, Bharucha AE, et al. Performance characteristics of scintigraphic colon transit measurement in health and irritable bowel syndrome and relationship to bowel functions. Neurogastroenterol Motil. 2010;22:415-423.
16. Camilleri M, Zinsmeister AR. Towards a relatively inexpensive, noninvasive, accurate test for colonic motility disorders. Gastroenterology. 1992;103:36-42.
17. Trentacosti AM, He R, Burke LB, Griebel D, Kennedy DL. Evolution of clinical trials for irritable bowel syndrome: issues in end points and study design. Am J Gastroenterol. 2010;105:731-735.